SCHEMBL1029949

SCHEMBL1029949

CC=C=COC(=O)CCCCC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.46
TSHR P16473 2/20 0.43
LMNA P02545 3/20 0.43
PAM P19021 2/20 0.42
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41
CES2 O00748 4/20 0.40
CES1 P23141 4/20 0.40
AKR1B1 P15121 1/20 0.39
ALDH1A1 P00352 2/20 0.39
DNM1 Q05193 1/20 0.39
POLB P06746 1/20 0.39
POLA1 P09884 1/20 0.39
NAAA Q02083 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.38
SLC22A8 Q8TCC7 1/20 0.38
GPR84 Q9NQS5 1/20 0.38
PPARG P37231 1/20 0.38
PPARD Q03181 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14914049 0.98 DGKA (0.48) DGKATSHRLMNAPAMMAPT
SCHEMBL1025349 0.98 DGKA (0.48) DGKATSHRLMNAPAMMAPT
SCHEMBL28232708 0.98 DGKA (0.48) DGKATSHRLMNAPAMMAPT
SCHEMBL2308844 0.94 DGKA (0.38) DGKATSHRLMNAPAMMAPT
SCHEMBL3252650 0.86 ALDH1A1 (0.44) TSHRCES2CES1ALDH1A1
SCHEMBL28080240 0.80 DGKA (0.42) DGKATSHRLMNAPAMMAPT
SCHEMBL22557779 0.80 DGKA (0.44) DGKATSHRLMNAPAMMAPT
SCHEMBL15708072 0.79 LMNA (0.53) DGKATSHRLMNAPAMMAPT
SCHEMBL11662066 0.79
SCHEMBL451966 0.78 DGKA (0.54) DGKATSHRLMNAPAMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS RETINA FOUND OF THE SOUTHWEST (US) 2022-12-29 US claimed
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS RETINA FOUND OF THE SOUTHWEST (US) 2022-12-29 US disclosed
CN-112741816-A Novel colon drug delivery system 江苏集萃新型药物制剂技术研究所有限公司 2021-05-04 CN disclosed
CN-211122902-U Vehicle-mounted alcohol tester 四川工商学院 2020-07-28 CN disclosed
CN-111372950-A VEGFR-antibody light chain fusion proteins 免疫苏醒公司 2020-07-03 CN disclosed
CN-111214701-A Implants for localized drug delivery and methods of use thereof 加利福尼亚大学董事会 2020-06-02 CN disclosed
EP-2171021-B1 USE OF A CONDUCTIVITY IMPROVER IN A HYDROCARBON COMPOSITION INNOSPEC LTD (GB) 2020-04-01 EP disclosed
CN-106573133-B Implants for localized drug delivery and methods of use thereof 加利福尼亚大学董事会 2020-03-03 CN disclosed
EP-2102317-B1 ADDITIVE, FUEL COMPOSITION, METHOD AND USE INNOSPEC LTD (GB) 2018-10-17 EP disclosed
EP-1640438-B1 Improvements in Fuel Oils INFINEUM INT LTD (GB) 2017-08-30 EP disclosed
WO-1996028523-A1 FUEL OIL ADDITIVES AND COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-09-19 WO disclosed
WO-1996022344-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL LIMITED (GB) 1996-07-25 WO disclosed
EP-0721492-A1 ADDITIVES AND FUEL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-07-17 EP disclosed
WO-1996018707-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1996018708-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1996018706-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1996-06-20 WO disclosed
WO-1995033805-A1 FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-12-14 WO disclosed
WO-1995033021-A1 OIL ADDITIVES AND COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-12-07 WO disclosed
WO-1995003377-A1 ADDITIVES AND FUEL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1995-02-02 WO disclosed
WO-1994017159-A1 OIL AND FUEL OIL COMPOSITIONS EXXON CHEMICAL PATENTS INC. (US) 1994-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409526-A1 COMPOUNDS AND IMPLANTS FOR TREATING OCULAR DISORDERS PDE6C, STRA6, PDE6A DGKA 2035/4885TSHR 1021/4885LMNA 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.